BIG4-11 APHINITY

A randomised, multicentre, double blind, placebo controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2+ primary breast cancer.

Disease site: Breast cancer

Treatment Modality: Combination therapy

Status: In follow-up

Trial details

APHINITY is coordinated by the Breast International Group (BIG) with the ICR-CTSU providing collaborative support in the UK.

Primary objectives:

To compare invasive disease-free survival (IDFS) in patients with HER2-positive breast cancer randomized to chemotherapy plus one year of trastuzumab plus placebo or chemotherapy plus one year of trastuzumab plus pertuzumab.

Secondary objectives:

To compare invasive disease-free survival including second non-breast cancers, disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), distant recurrence-free interval (DRFI), cardiac safety, overall safety and health-related quality of life (HRQL) in the two treatment arms.

Chief Investigator: Professor David Cameron, Edinburgh University (UK CI)

ICR-CTSU Scientific Lead: Professor Judith Bliss

ISRCTN: N/A

Sponsor: F. Hoffman-La Roche Ltd and Genentech, Inc.

Funder: F. Hoffman-La Roche Ltd

Further information

Further information, including contact details for the trial may be found on the BIG website.

Monthly accrual figures are available from the UKCRN Portfolio

breast cancer cell
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer

12/12/24

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
See full story
Breast cancer cell spheroid blue and purple
New understanding of aggressive form of breast cancer paves the way for tests and treatments

10/12/24

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
See full story